glucose, (beta-d)-isomer has been researched along with Hyperpotassemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Anker, SD; Butler, J; Ferreira, JP; Filippatos, G; Januzzi, JL; Packer, M; Pocock, S; Schueler, E; Steubl, D; Zannad, F; Zeller, C | 1 |
| Agarwal, R; Elsäßer, A; Hauske, SJ; Kadowaki, T; Levin, A; Nangaku, M; Ritter, I; Steubl, D; Tuttle, KR; Wanner, C; Wheeler, DC | 1 |
| Cosentino, F; Dhingra, NK; Pandey, AK; Verma, S | 1 |
| Anker, SD; Butler, J; Ferreira, JP; Filipattos, G; Kraus, BJ; Packer, M; Pocock, SJ; Ritter, I; Schüler, E; Zannad, F | 1 |
| Anker, SD; Brueckmann, M; Butler, J; Ferreira, JP; Filippatos, G; Jamal, W; Packer, M; Pocock, SJ; Schueler, E; Steubl, D; Zannad, F | 1 |
| Bauersachs, J; Berliner, D | 1 |
| Mikhail, N | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Hyperpotassemia
| Article | Year |
|---|---|
New drugs: big changes in conservative heart failure therapy?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea | 2019 |
3 trial(s) available for glucose, (beta-d)-isomer and Hyperpotassemia
| Article | Year |
|---|---|
Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Benzhydryl Compounds; Chronic Disease; Glucosides; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Stroke Volume | 2022 |
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2022 |
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
Topics: Aged; Benzhydryl Compounds; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Glucosides; Heart Failure; Humans; Hyperkalemia; Kidney Function Tests; Male; Mineralocorticoid Receptor Antagonists; Outcome and Process Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Withholding Treatment | 2021 |
3 other study(ies) available for glucose, (beta-d)-isomer and Hyperpotassemia
| Article | Year |
|---|---|
Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.
Topics: Benzhydryl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Potassium; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Glucosides; Heart Failure; Humans; Hyperkalemia; Hypokalemia; Potassium; Stroke Volume; Ventricular Function, Left | 2022 |
Safety of canagliflozin in patients with type 2 diabetes.
Topics: Canagliflozin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hyperkalemia; Hypoglycemic Agents; Lipids; Male; Thiophenes; Urinary Tract Infections; Urination | 2014 |